EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease

Jon-Anders Tunold, Manuela M X Tan, Shunsuke Koga iD, Hanneke Geut, Annemieke J M Rozemuller, Rebecca Valentino, Hiroaki Sekiya, Nicholas B Martin, Michael G Heckman, Jose Bras, Rita Guerreiro, Dennis W Dickson iD und 4 weitere

Brain · 03.10.2023 · 146 (10) · 4077-4087

DOI: 10.1093/brain/awad183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 29.05.2023. Verfasst von Jon-Anders Tunold und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Oslo University Hospital, 0424 Oslo, Norway. Hauptthemen laut MEDLINE: Lewy Body Disease, Alzheimer Disease, Parkinson Disease. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, South-Eastern Norway Regional Health Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intraneuronal accumulation of misfolded α-synuclein is the pathological hallmark of Parkinson’s disease and dementia with Lewy bodies, often co-occurring with variable degrees of Alzheimer’s disease related neuropathology. Genetic association studies have successfully identified common variants associated with disease risk and phenotypic traits in Lewy body disease, yet little is known about the genetic contribution to neuropathological heterogeneity. Using summary statistics from Parkinson’s disease and Alzheimer’s disease genome-wide association studies, we calculated polygenic risk scores and investigated the relationship with Lewy, amyloid-β and tau pathology. Associations were nominated in neuropathologically defined samples with Lewy body disease from the Netherlands Brain Bank (n = 217) and followed up in an independent sample series from the Mayo Clinic Brain Bank (n = 394). We also generated stratified polygenic risk scores based on single-nucleotide polymorphisms annotated to eight functional pathways or cell types previously implicated in Parkinson’s disease and assessed for association with Lewy pathology in subgroups with and without significant Alzheimer’s disease co-pathology. In an ordinal logistic regression model, the Alzheimer’s disease polygenic risk score was associated with concomitant amyloid-β and tau pathology in both cohorts. Moreover, both cohorts showed a significant association between lysosomal pathway polygenic risk and Lewy pathology, which was more consistent than the association with a general Parkinson’s disease risk score and specific to the subset of samples without significant concomitant Alzheimer’s disease related neuropathology. Our findings provide proof of principle that the specific risk alleles a patient carries for Parkinson’s and Alzheimer’s disease also influence key aspects of the underlying neuropathology in Lewy body disease. The interrelations between genetic architecture and neuropathology are complex, as our results implicate lysosomal risk loci specifically in the subset of samples without Alzheimer’s disease co-pathology. Our findings hold promise that genetic profiling may help predict the vulnerability to specific neuropathologies in Lewy body disease, with potential relevance for the further development of precision medicine in these disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lewy Body DiseaseAlzheimer DiseaseParkinson DiseaseHumansGenome-Wide Association StudyAmyloid beta-PeptidesLysosomes

Stichwörter der Autor:innen

Lewy body diseaseParkinson’s diseasegeneticslysosomal pathwayneuropathology

Substanzen

Amyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Neurology, Oslo University Hospital, 0424 Oslo, Norway.
  • Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0372 Oslo, Norway.
  • Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
  • Department of Pathology, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
  • Program Neurodegeneration, Amsterdam Neuroscience, 1081 HV Amsterdam, The Netherlands.

ORCID-Profile: Shunsuke Koga, Dennis W Dickson, Lasse Pihlstrøm

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • South-Eastern Norway Regional Health Authority
  • NIH
  • American Parkinson Disease Association
  • Dementia Association

Zitieren

APA

Tunold, J. A., Tan, M. M. X., Koga, S., Geut, H., Rozemuller, A. J. M., Valentino, R., Sekiya, H., Martin, N. B., Heckman, M. G., Bras, J., Guerreiro, R., Dickson, D. W., Toft, M., van de Berg, W. D. J., Ross, O. A., & Pihlstrøm, L. (2023). Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease. Brain, 146(10), 4077-4087. https://doi.org/10.1093/brain/awad183

Vancouver

Tunold JA, Tan MMX, Koga S, Geut H, Rozemuller AJM, Valentino R, et al. Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease. Brain. 2023;146(10):4077-4087. doi:10.1093/brain/awad183

BibTeX
@article{Tunold2023,
  author = {Tunold, Jon-Anders and Tan, Manuela M X and Koga, Shunsuke and Geut, Hanneke and Rozemuller, Annemieke J M and Valentino, Rebecca and Sekiya, Hiroaki and Martin, Nicholas B and Heckman, Michael G and Bras, Jose and Guerreiro, Rita and Dickson, Dennis W and Toft, Mathias and van de Berg, Wilma D J and Ross, Owen A and Pihlstrøm, Lasse},
  title = {Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {10},
  pages = {4077--4087},
  doi = {10.1093/brain/awad183}
}
Kostenlos starten →